Achmea Investment Management B.V. Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

Achmea Investment Management B.V. raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 46.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 35,221 shares of the life sciences company's stock after purchasing an additional 11,200 shares during the quarter. Achmea Investment Management B.V.'s holdings in Illumina were worth $4,706,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new position in shares of Illumina in the fourth quarter worth about $32,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina during the 4th quarter worth about $45,000. Finally, TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after purchasing an additional 141 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 0.2 %

Shares of Illumina stock traded down $0.20 during mid-day trading on Wednesday, hitting $84.96. The stock had a trading volume of 2,612,128 shares, compared to its average volume of 2,583,026. The firm has a 50-day moving average of $111.38 and a two-hundred day moving average of $129.20. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $13.46 billion, a P/E ratio of -11.06, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research analyst reports. Citigroup reduced their price target on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Canaccord Genuity Group reduced their price target on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research report on Tuesday, March 11th. Royal Bank of Canada reduced their price target on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 12th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.